Recruiting
Phase 3

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT04181060

Conditions

Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma

Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

Stage IIIB Lung Cancer AJCC v8

Stage IV Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bevacizumab

Biospecimen Collection

Computed Tomography

Echocardiography

Magnetic Resonance Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information